Through its proprietary Immune Repertoire Capture technology, Atreca is able to profile a patient's immune response at the single-cell level, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of the antigen. This technology has been validated through partnerships with major pharmaceutical companies, academic institutions, and governmental entities. Atreca focuses on therapeutic areas where immune responses play a crucial role, particularly in oncology. The company's goal is to develop innovative cancer immunotherapies that optimize anti-tumor immune responses in synergy with checkpoint inhibitors and immune activators.